The SLC3A1 gene helps the kidneys and small intestine move certain amino acids, especially cystine, back into the body instead of losing them in urine. This gene helps your body keep cystine levels more balanced. When it does not work properly, cystine can build up in urine and form repeated kidney stones, which may cause pain, blood in the urine, or urinary blockage. Pathogenic variants in the SLC3A1 gene are a known cause of cystinuria.
What is a gene?
Genes are stretches of DNA that provide cells with instructions to make molecules or direct processes in the body. Some genes hold the code for proteins, which do much of the work inside cells. Others are mainly involved in controlling when certain processes take place, where they occur, and how strongly they run. Together, genes affect how the body develops and works, and they can influence how you respond to food, stress, or medicines. If you want to go into this topic in more detail, you can find more in the LearnHub.
Overview
SLC3A1Gene function
What if the gene works
The SLC3A1 gene helps the kidneys and small intestine move certain amino acids, especially cystine, back into the body. This supports normal nutrient handling and helps keep too much cystine from building up in urine.
Risk
What if the gene does not work
Variants in the SLC3A1 gene can cause cystinuria, where the kidneys do not reabsorb cystine properly. This can lead to cystine kidney stones from childhood. Milder or more severe variants may affect when stones start and how often they return.
Treatment
What does that mean for your treatment
A pathogenic variant in the SLC3A1 gene supports cystinuria management aimed at lowering cystine in urine. Treatment usually centers on high fluid intake, urine alkalinization, and reduced sodium intake; some people also need cystine-binding medicines such as tiopronin. No SLC3A1-specific drug choice beyond standard cystinuria care is established.
Conditions associated with SLC3A1
Gene function
What if the gene works
Your kidneys and small intestine regularly recover valuable amino acids so your body can reuse them. The SLC3A1 gene helps your body handle this step by supporting a transporter in the cell surface. This helps explain how the SLC3A1 gene supports amino acid reabsorption in the kidneys and gut.
In the kidneys, the SLC3A1 gene helps cells take back cystine, lysine, arginine, and ornithine after blood is filtered. This keeps these useful building blocks in the body instead of letting them pass into urine.
In the small intestine, its protein helps absorb cystine and several amino acids from digested food. This supports your body’s amino acid supply for making proteins and carrying out routine cell work.
Its protein works as part of a two part transporter with a partner made from the SLC7A9 gene. Together they sit in the cell membrane and move these amino acids from the fluid outside the cell into the cell.
What is a variant?
A genetic variant is a small alteration in the DNA sequence of a gene. These changes are common and help account for normal human diversity, such as differences in appearance, metabolism, or how the body responds to environmental influences. Many variants do not cause any noticeable effect and simply represent natural genetic variation. In some situations, though, a variant can change how a gene functions more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Many variants in the SLC3A1 gene change the rBAT protein’s shape, stability, or delivery to the cell surface, so it may not pair properly with the SLC7A9 transporter. This shows how variants influence the SLC3A1 gene's function: cystine transport falls because activity is partly reduced or nearly lost. Milder variants may leave some transport working, while more severe variants can stop it almost entirely and are often linked to earlier or more frequent cystine kidney stones.
How variants are linked to conditions
Pathogenic variants in the SLC3A1 gene cause cystinuria, so discussions of the SLC3A1 gene and cystinuria usually focus on repeated cystine kidney stones. This inherited condition can lead to stones starting in childhood, the teen years, or adulthood, with symptoms such as side pain, blood in the urine, or frequent stone episodes. In most affected people, variants are found in both copies of the gene.
A variant is not necessarily a diagnosis
Genetic variants are a routine feature of human biology and are widespread across the population. Most do not directly affect health and simply reflect normal human diversity. For many genes, having a variant associated with a condition points to a possible link rather than a certain diagnosis, particularly when several genes and environmental factors play a role. In some situations, though, one well-characterized variant in a particular gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For people with changes in the SLC3A1 gene, the main issue is a higher chance of cystine kidney stones, and that risk is largely driven by the gene change itself. Stone problems can become more likely with low fluid intake, high salt intake, and eating a lot of animal protein. These steps may help lower stone formation, but they do not remove the underlying genetic condition.
Inheritance of SLC3A1 variants
For families asking how SLC3A1 gene variants are inherited, the well-established pattern for SLC3A1-related cystinuria is autosomal recessive. This means a person usually inherits one variant in the SLC3A1 gene from each parent. When both parents carry one variant, each pregnancy has a 25% chance of a child inheriting both variants, a 50% chance of being a carrier, and a 25% chance of inheriting neither variant. Parents of an affected child are often healthy carriers.
What does my SLC3A1 result mean for my family?
For many living with an SLC3A1-related kidney stone condition, the family pattern is usually recessive, which means brothers and sisters may also be affected or may carry the same change without symptoms. Parents are often healthy carriers, and other close relatives may be carriers too. Children usually will not have the condition unless the other parent also carries a change in SLC3A1, but they may inherit a carrier result.
Genetic information
Genetic testing
How you find out about variants
Genetic testing for SLC3A1 variants usually uses a blood or saliva sample, and how genetic testing for SLC3A1 works is straightforward: a lab reads the gene’s DNA code and checks for missing or extra pieces. Results can show whether you carry a variant or have two variants that help explain cystinuria.
When should I consider getting a genetic test?
Consider testing for changes in the SLC3A1 gene if you have repeated kidney stones, especially starting in childhood or the teen years, or if testing suggests cystine stones, a common sign of an inherited condition called cystinuria. It can also help if cystinuria runs in your family.
A genetic result is only one part of your health story
A genetic result can be informative, but how much it reveals varies depending on the condition and the specific variant involved. Many factors, including lifestyle, environment, age, and medical history, influence how the body works over time. For some conditions, especially those shaped by many genes, genetic information provides context rather than certainty and is best interpreted alongside other parts of care. In other situations, a genetic result may offer a clear answer. In areas like medication response, genetic results can also help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. This helps explain why the same treatment works well for one person but less well for another, or why some people are more likely to notice side effects. Small differences in genes can change how the body absorbs, breaks down, transports, or responds to a drug, and these differences are common.
What is Pharmacogenetics?
Pharmacogenetics looks at how genetic differences can shape a person’s response to medications. It studies connections between genes and drugs to help explain why the same treatment may work differently from one person to another. For many medications, genes can affect how the body processes a drug or how strong its effects are. This information can support more informed, individualized treatment decisions. You can read more about this topic in the LearnHub.
Drugs influenced by the SLC3A1 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medicine choice or dose. For questions about side effects, new symptoms, kidney stone treatment, or how any medicine fits your overall health, speak with your doctor or pharmacist.
History
SLC3A1 entered medical genetics through work on cystinuria, a condition recognized for centuries because some people repeatedly formed kidney stones from a young age. Families and communities once noticed patterns that seemed to pass from parent to child. In the 20th century, researchers showed that cystinuria followed an inherited pattern, helping move the condition from bedside observation into modern genetics. During the 1990s, the SLC3A1 gene was identified as one of the key genes linked to this condition, which marked an important step in understanding why affected families could look similar across generations. From these first observations, research expanded steadily, and scientists later found that variants in another gene, SLC7A9, can also cause cystinuria.